1-甲基-4-(4-硝基苯基)哌嗪 | 16155-03-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-甲基-4-(4-硝基苯基)哌嗪
• 英文名称: 1-methyl-4-(4-nitrophenyl)piperazine
• 英文别名: 4-(4-methylpiperazine)nitrobenzene；N-methyl,N'-(4-nitrophenyl)piperazine
• CAS: 16155-03-6
• 化学式: C₁₁H₁₅N₃O₂
• mdl: MFCD00101003
• 分子量: 221.259
• InChiKey: GZNDUKANJZIZOT-UHFFFAOYSA-N

物化性质

• 熔点：
  109-111°C
• 沸点：
  369.5±37.0 °C(Predicted)
• 密度：
  1.198±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  52.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Methyl-4-(4-nitrophenyl)piperazine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Methyl-4-(4-nitrophenyl)piperazine
CAS number: 16155-03-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H15N3O2
Molecular weight: 221.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基-4-(4-硝基苯基)哌嗪 在 palladium on activated charcoal 、 一水合肼 作用下， 以 异丙醇 为溶剂， 生成 4-(4-甲基哌嗪)苯胺
  参考文献：
  名称：

  吡咯并[2,3-d]嘧啶衍生物作为EGFR突变NSCLC细胞酪氨酸激酶抑制剂的合成及生物活性

  摘要：

  EGFR突变是NSCLC治疗中的一个持续挑战，需要不断更新EGFR TKI候选药物。吡咯并嘧啶是一组适用于定制药物开发的多功能支架。然而，在第三代共价 EGFR-TKI 领域中没有太多此类药效团的先例被研究。在此，一系列 pyrrolo[2,3- d] 通过优化的 Buchwald-Hartwig C-N 交叉偶联反应合成了能够以共价方式阻断突变 EGFR 活性的嘧啶衍生物。在分子和细胞水平上研究了它们的初步生物活性和相应的抑制机制途径。与对照化合物相比，几种化合物表现出增加的生物活性和增强的选择性。值得注意的是，与正常 HBE 细胞相比，化合物12i选择性地抑制具有 EGFR 激活突变的 HCC827 细胞，其功效提高了 493 倍。增强的选择性也通过激酶酶测定得到证实，测试化合物选择性抑制 T790 M 激活突变 EGFR（IC 50值 0.21 nM）与野生型 EGFR（IC 50值为

  DOI：

  10.1016/j.ejmech.2021.113711
• 作为产物：
  描述：

  1-(4-硝基苯基)哌嗪 在 C₂₅H₄₂N₆Rh⁽¹⁺⁾*CF₃O₃S^(1-) 、 二苯基硅烷 作用下， 以 二氯甲烷 为溶剂， 25.0 ℃ 、2.53 MPa 条件下， 反应 24.0h， 生成 1-甲基-4-(4-硝基苯基)哌嗪
  参考文献：
  名称：

  螯合双（1,2,3-三唑-5-亚烷基）铑配合物：氢化硅烷化反应的多功能催化剂

  摘要：

  NHC-铑配合物（NHC = N-杂环卡宾）已被广泛用作氢化硅烷化反应的有效催化剂。但是，底物主要限于反应性羰基化合物（醛和酮）或碳-碳多重键。在这里，我们描述了新开发的螯合双（tz NHC）-铑配合物（tz = 1,2,3-三唑-5-亚烷基）在几种还原转化中的应用。使用这些催化剂，已经在温和的反应条件下实现了使用二氧化碳的胺的正式还原甲基化，酰胺和羧酸的氢化硅烷化以及使用羧酸的胺的还原烷基化。

  DOI：

  10.1002/adsc.201500875

文献信息

• [DE] PI3-KINASEN<br/>[EN] PI3 KINASES<br/>[FR] PI3-KINASES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2006040279A1

  公开（公告）日：2006-04-20

  Es werden neue Verbindungen der Formel (1) bereitgestellt, die aufgrund ihrer pharmazeutischen Wirksamkeit als PI3-Kinase Modulator zur Anwendung auf therapeutischem Gebiet zur Behandlung von entzündlichen oder allergischen Erkrankungen gelangen können. Beispielhaft seien hier entzündliche und allergische Atemwegserkrankungen, entzündliche Erkrankungen des Magen-Darm-Traktes und des Bewegungsapparates, entzündliche und allergische Hauterkrankungen, entzündliche Augenerkrankungen, Erkrankungen der Nasenschleimhaut, entzündliche oder allergische Krankheitszustände, bei denen Autoimmun-Reaktionen beteiligt sind oder Nierenentzündungen genannt.

  提供公式（1）的新颖化合物，由于其药理活性可作为PI3激酶调节剂应用于治疗领域，用于治疗炎性疾病或过敏性疾病。例如，这里可以列举的包括炎性和过敏性呼吸道疾病、炎性疾病、胃肠道的运动系统、炎性和过敏性皮肤病、炎性疾病、鼻粘膜疾病、炎症或过敏性疾病，其中涉及自身免疫反应或肾盂肾炎。
• Pyrido[2,3-<i>d</i>]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4
  作者：Scott N. VanderWel、Patricia J. Harvey、Dennis J. McNamara、Joseph T. Repine、Paul R. Keller、John Quin、R. John Booth、William L. Elliott、Ellen M. Dobrusin、David W. Fry、Peter L. Toogood

  DOI：10.1021/jm049355+

  日期：2005.4.1

  Inhibition of the cell cycle kinase, cyclin-dependent kinase-4 (Cdk4), is expected to provide an effective method for the treatment of proliferative diseases such as cancer. The pyrido[2,3-d]pyrimidin-7-one template has been identified previously as a privileged structure for the inhibition of ATP-dependent kinases, and good potency against Cdks has been reported for representative examples. Obtaining

  预期细胞周期激酶，细胞周期蛋白依赖性激酶4（Cdk4）的抑制将为治疗增生性疾病（例如癌症）提供有效的方法。以前已经鉴定了吡啶并[2,3-d]嘧啶-7-模板作为抑制ATP依赖性激酶的优先结构，并且已经报道了代表性实例对Cdks的良好效力。获得对单个Cdk酶，特别是Cdk4的选择性一直具有挑战性。在这里，我们报道在吡啶基[2,3-d]嘧啶-7-一个模板的C-5位置处引入甲基取代基足以赋予Cdk4相对于其他Cdks和代表性酪氨酸激酶优异的选择性。进一步的优化导致鉴定出在体外对人肿瘤细胞表现出有效抗增殖活性的高效Cdk4抑制剂。评估了选择性最强的Cdk4抑制剂对小鼠中MDA-MB-435人乳腺癌异种移植物的抗肿瘤活性。
• FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF
  申请人：Sarepta Therapeutics, Inc.

  公开号：US20140330006A1

  公开（公告）日：2014-11-06

  Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

  提供了包含修改的亚单位间连接和/或修改的3'和/或5'-末端基团的功能修饰寡核苷酸类似物。所公开的化合物对于治疗需要抑制蛋白质表达或纠正异常mRNA剪接产物以产生有益治疗效果的疾病是有用的。
• Substituted 4-amino-thiazol-2-yl compounds as cyclin-dependent kinase inhibitors
  申请人：Agouron Pharmaceuticals Inc.

  公开号：US06569878B1

  公开（公告）日：2003-05-27

  Pharmaceutical compositions containing effective amounts of CDK-inhibiting diaminothiazole compounds of the following formula (where R1 and R2 are as defined in the specification) or their salts, or prodrugs or active metabolites of such compounds or salts, are useful for treating disorders and diseases such as cancer: In preferred embodiments, R1 and R2 are independently unsubstituted or substituted carbocyclic or heterocyclic aryl ring structures. Compounds where R2 is ortho-substituted aryl are especially potent inhibitors of CDKs such as CDK4.

  含有以下式（其中R1和R2如规范中定义）的CDK抑制二氨基噻唑化合物或其盐、前药或这些化合物或盐的活性代谢物的有效量的药物组合物，对于治疗癌症等疾病和疾病是有用的： 在优选实施例中，R1和R2独立地是未取代或取代的碳环或杂环芳基环结构。其中R2为邻位取代芳基的化合物特别是CDK4的有效抑制剂。
• 5-Piperazinyl-3-sulfonylindazoles as Potent and Selective 5-Hydroxytryptamine-6 Antagonists
  作者：Kevin G. Liu、Albert J. Robichaud、Ronald C. Bernotas、Yinfa Yan、Jennifer R. Lo、Mei-Yi Zhang、Zoe A. Hughes、Christine Huselton、Guo Ming Zhang、Jean Y. Zhang、Dianne M. Kowal、Deborah L. Smith、Lee E. Schechter、Thomas A. Comery

  DOI：10.1021/jm1007825

  日期：2010.11.11

  Herein we report the identification of a novel series of 5-piperazinyl-3-sulfonylindazoles as potent and selective 5-HT6 antagonists. The synthesis, SAR, and pharmacokinetic and pharmacological activities of some of the compounds including 3-(naphthalen-1-ylsulfonyl)-5-(piperazin-1-yl)-1H-indazole (WAY-255315 or SAM-315) will be described.

  作为开发中枢神经系统疾病病原体的努力的一部分，我们一直专注于5-HT 6受体，以鉴定有效的和选择性的配体，以增强认知能力。在本文中，我们报告鉴定出一系列新型的5-哌嗪基-3-磺酰基吲唑作为有效的和选择性的5-HT 6拮抗剂。包括3-（萘-1-基磺酰基）-5-（哌嗪-1-基）-1 H-吲唑（WAY-255315或SAM-315）在内的某些化合物的合成，SAR，药代动力学和药理活性被描述。